000 | 01947 a2200505 4500 | ||
---|---|---|---|
005 | 20250515094912.0 | ||
264 | 0 | _c20080131 | |
008 | 200801s 0 0 eng d | ||
022 | _a1478-3223 | ||
024 | 7 |
_a10.1111/j.1478-3231.2007.01609.x _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aYen, Yi-Hao | |
245 | 0 | 0 |
_aChanges in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy. _h[electronic resource] |
260 |
_bLiver international : official journal of the International Association for the Study of the Liver _cDec 2007 |
||
300 |
_a1349-55 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 |
_aAlanine Transaminase _xblood |
650 | 0 | 4 |
_aDNA, Viral _xblood |
650 | 0 | 4 |
_aDrug Resistance, Viral _xdrug effects |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aFollow-Up Studies |
650 | 0 | 4 |
_aHepatitis B Antibodies _xblood |
650 | 0 | 4 |
_aHepatitis B e Antigens _xblood |
650 | 0 | 4 |
_aHepatitis B virus _xdrug effects |
650 | 0 | 4 |
_aHepatitis B, Chronic _xdrug therapy |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aLamivudine _xtherapeutic use |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aMutation |
650 | 0 | 4 | _aPredictive Value of Tests |
650 | 0 | 4 |
_aReverse Transcriptase Inhibitors _xtherapeutic use |
700 | 1 | _aLu, Sheng-Nan | |
700 | 1 | _aChen, Chien-Hung | |
700 | 1 | _aWang, Jing-Houng | |
700 | 1 | _aWu, Chun-Mei | |
700 | 1 | _aHung, Chao-Hung | |
700 | 1 | _aTseng, Po-Lin | |
700 | 1 | _aHu, Tsung-Hui | |
700 | 1 | _aChangchien, Chi-Sin | |
700 | 1 | _aLee, Chuan-Mo | |
773 | 0 |
_tLiver international : official journal of the International Association for the Study of the Liver _gvol. 27 _gno. 10 _gp. 1349-55 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1478-3231.2007.01609.x _zAvailable from publisher's website |
999 |
_c17551519 _d17551519 |